- Home
- SRG vs MOLN Comparison
SRG vs MOLN Comparison
Compare SRG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRG | MOLN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.4M | 170.5M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRG | MOLN |
|---|---|---|
| Price | $2.04 | $4.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 143.7K | 1.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $2.01 | $3.53 |
| 52 Week High | $4.56 | $5.36 |
Technical Indicators
Market Signals| Indicator | SRG | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 53.74 |
| Support Level | N/A | $4.13 |
| Resistance Level | $2.74 | $4.51 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 17.65 | 46.67 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.